raul pellini

Chief

Istituto Regina Elena
Country flagItaly

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Raul Pellini is the Chief at Istituto Regina Elena in Italy. His research focuses on head and neck oncology, with recent publications examining prognostic markers, imaging techniques, and the tumor microenvironment in squamous cell carcinoma. He has contributed to studies on radiotherapy impacts, surgical interventions, and machine learning applications in predicting oncological outcomes.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Objective Current guidelines indicate postoperative radiotherapy (PORT) in oral squamous cell carcinoma (OSCC) with perineural invasion (PNI), however, its real benefit has never been proven. The aim of our study is to investigate the benefit of PORT in OSCC patients with PNI in terms of survival and disease control. Data Sources The Pubmed/MEDLINE, Cochrane Library, and Scopus databases. Review Methods Patients with PNI + OSCC treated with primary surgery were extracted from the included studies. The pooled logHR was calculated by comparing patients who underwent PORT to those who underwent only observation for overall survival (OS), disease‐specific survival (DSS), disease‐free survival (DFS), and locoregional control (LRC). Results About 690 patients with primary OSCC and PNI were included from nine studies. 374 (54.2%) patients underwent PORT, while 316 (45.8%) underwent observation. Analyses showed non‐significant difference between the two groups for OS (HR: 1.01; 95% CI: 0.38–2.69), DSS (HR: 2.03; 95% CI: 0.54–7.56), and LRC (HR: 0.89; 95% CI: 0.53–1.50). They showed a significant difference in terms of DFS (HR: 0.86; 95% CI: 0.77–0.97). Conclusion The real benefit of PORT in OSCC patients with PNI is still unclear, although it may have a positive impact on DFS. Clinicians should consider individual patient's characteristics, tumor factors, and treatment goals when deciding whether to recommend PORT. Further studies are needed to clarify which entity of PNI really benefits from PORT. Level of Evidence NA Laryngoscope , 134:2019–2027, 2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (10)

Paola Nisticò

IRCCS Regina Elena National Cancer Institute

ITALY
View details

Alessandro Corsi

Sapienza University

ITALY
View details

Rossella Sgarzani

Associate Professor in Plastic Surgery

University of Bologna

ITALY
View details

Armando De Virgilio

-

ITALY
View details

Jelena Dimitrov

University of Salerno

ITALY
View details

Giulia Orlandi

Istituto Dermatologico San Gallicano

ITALY
View details

Alessandra Rosati

Associate Professor

University of Salerno

ITALY
View details

Francesco Antonio Salzano

Full Professor

University of Salerno

ITALY
View details

Pasquale Viola

Università degli Studi Mediterranea di Reggio Calabria

ITALY
View details

Gerardo Petruzzi

Istituto Regina Elena

ITALY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.